Please login to the form below

Not currently logged in

New oral contraceptive launched in Europe

Bayer Schering Pharma has begun the rollout of its new oral contraceptive Qlaira in several European countries

Bayer Schering Pharma has begun the rollout of its new oral contraceptive Qlaira (estradiol valerate/dienogest) in several European countries, with more to follow from autumn 2009.

Qlaira is the first of a new class of oral contraceptives, delivering a form of oestrogen (estradiol) identical to that produced by the female reproductive system. Oral contraceptives available to women up until now have contained the oestrogen component ethinylestradiol.

Qlaira uses a unique dosing regimen to combine the oestrogen element of the pill with the progestin in such a way to deliver the correct levels of hormones at the right time in a woman's monthly cycle, resulting in reliable contraception and good cycle control.

"We are highly delighted that we will now bring Qlaira – our latest innovation in the field of contraception – to women all over Europe," said Dr Phil Smits, head of Women's Healthcare at Bayer Schering Pharma.

The company is also looking to gain approval for the additional indication for the treatment of prolonged heavy and frequent bleeding in women who wish to use oral contraception. No other contraception is currently approved for treating this condition.

14th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...